Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares conducted on March 3, 2026. The filing was submitted on March 4, 2026. The transaction was executed by BNP Paribas SA acting as a broker under a non-discretionary agreement announced on February 17, 2026, as part of GSK's existing share buyback programme.
Key Financial Metrics and Transaction Details
The filing details a specific repurchase event rather than providing comprehensive financial statements (revenue, profit, or cash flow are not included in this specific filing).
- Shares Purchased: 630,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 2,116.00 GBp; Highest price paid was 2,169.00 GBp.
- Volume-Weighted Average Price (VWAP): 2,139.22 GBp.
- Trading Venues: Purchases were made across BATE, CHIX, and XLON (London Stock Exchange).
- Programme Progress: Since February 17, 2026, the Company has purchased a total of 5,266,000 ordinary shares.
Material Changes and Capital Structure
Following the purchase on March 3, 2026, the Company's capital structure was updated as follows:
- Treasury Shares Held: 245,157,094 ordinary shares.
- Shares in Issue (excluding Treasury): 4,071,005,394 ordinary shares.
- Total Voting Rights: 4,071,005,394.
- Treasury Voting Percentage: The percentage of voting rights attributable to shares held in treasury is 6.02%.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in GSK's Annual Report on Form 20-F for 2024 and Q4 Results for 2025.
Key Facts for Investor Verification
- Verify the total remaining authorization under the existing buyback programme to assess future repurchase capacity.
- Confirm the impact of the 6.02% treasury shareholding on earnings per share (EPS) calculations and voting rights thresholds.
- Review the non-discretionary agreement terms announced on February 17, 2026, to understand the scope and duration of the current buyback activity.
- Note that this filing does not contain revenue, profit, or cash flow data; refer to the most recent Form 20-F or quarterly results for operational metrics.